Novartis AG NOVN

SWX: NOVN | ISIN: CH0012005267   20/03/2026
115,60 CHF (-1,10%)
(-1,10%)   20/03/2026
Grafiek Novartis AG Grafiek Novartis AG

Novartis AG in het nieuws

20 maart 2026 · Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline · Persbericht

13 maart 2026 · Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa · Persbericht

6 maart 2026 · Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting · Persbericht

27 februari 2026 · Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy · Persbericht

27 februari 2026 · Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU) · Persbericht

25 februari 2026 · Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients · Persbericht

24 februari 2026 · New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer · Persbericht

23 februari 2026 · Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU) · Persbericht

18 februari 2026 · Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU) · Persbericht

13 februari 2026 · Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy · Persbericht

Profiel Novartis AG

Farmaceutica
Gezondheidstechnologie
Medicinale en botanische productie
Productie

Mijn selecties